comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 16:23:31 - browse：126

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： How CRISPR works, explained in two minutes

leisure time

entertainment

WSS

Longer MASH drug regimen improved liver, Akero study finds

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Ancient Greek ideas underpin modern concepts of pregnancy

Failure, not just success, should guide future doctors

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Failure, not just success, should guide future doctors

Wikipedia

comprehensive

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Walensky prepares to leave CDC — and Congress — behind

Why Talkspace is targeting Medicare, a tricky market

Hepatitis C has a cure — but many Americans still lack access to it

Paxlovid rebound happens. Why and to whom are still a mystery

Alkermes shareholders re

$1 billion proposal to grow Boston, Massachusetts biotech

Hepatitis C has a cure — but many Americans still lack access to it

For AI in health care standards, federal regulators join with industry group

leisure time

Election results set back Medicaid expansion plans

Failure, not just success, should guide future doctors

Doctors push to include dialysis machines in emergency stockpile

$1 billion proposal to grow Boston, Massachusetts biotech

Harvard's David Sinclair gets blowback over aging

Harvard's David Sinclair gets blowback over aging

hotspot

leisure time

entertainment

hotspot